Latest Lucentis Stories
VANCOUVER, Dec. 9 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) ("QLT" or the "Company") welcomed the 6-month results from the Novartis-sponsored EVEREST study which were presented during a scientific review today by Novartis in Basel, Switzerland.
Investigators from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have shown, at 6 months in a small group of patients, that there is no difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration (AMD).
VANCOUVER, June 15 /PRNewswire-FirstCall/ - QLT Inc.
VANCOUVER, June 2 /PRNewswire-FirstCall/ - QLT Inc.
However, Off-Label Use of Avastin Will Take Market Share Away from Lucentis from 2012 to 2017, According to a New Report from Decision Resources WALTHAM, Mass., March 10 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that robust annual 17 percent growth in the age-related macular degeneration (AMD) market through 2012 will be driven primarily by expanding use of Genentech/Novartis Ophthalmics'...
Mean visual acuity letter scores increased similarly in all treatment groups VANCOUVER, Dec. 16 /PRNewswire-FirstCall/ - QLT Inc.
DR McGONAGLE'S put-down of NICE (Letters, August 28) as the "National Institute of Complete Embarrassment" does a disservice. NICE has produced final guidance for the drug Lucentis, now accepted for use throughout the UK.
WASHINGTON - What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing $60 per treatment and the other $2,000? In the case of Genentech Inc., nothing.
What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000?
The National Institute for Health and Clinical Excellence has recommended Novartis's Lucentis as a cost-effective therapy for all eligible patients with wet age-related macular degeneration.